|
Affiliation |
Director |
|
Laboratory Address |
5200 Kihara-Kiyotake-cho, Miyazaki City |
|
Laboratory Phone number |
+81-985-85-2968 |
|
Laboratory Fax number |
+81-985-85-6958 |
|
Homepage |
|
|
External Link |
|
KAMOTO Toshiyuki
|
|
|
Degree 【 display / non-display 】
-
博士（医学） ( 1997.7 京都大学 )
-
学士（医学） ( 1987.3 京都大学 )
Research Interests 【 display / non-display 】
-
urology, uro-oncology, laparoscopic surgery
-
腫瘍マーカー
-
腎移植
-
精巣癌
-
泌尿器腫瘍学
-
前立腺癌
-
内視鏡/体腔鏡手術
Research Areas 【 display / non-display 】
-
Life Science / Urology / urologic oncology
Education 【 display / non-display 】
-
Kyoto University Graduate School, Division of Medicine
- 1995.8
Country：Japan
-
Kyoto University Faculty of Medicine
- 1987.3
Country：Japan
Campus Career 【 display / non-display 】
-
University of Miyazaki Faculty of Medicine School of Medicine Department of Developmental and Urological-Reproductive Medicine, Urology Professor
2009.05 - 2024.09
-
University of Miyazaki Director
2024.10 - Now
-
University of Miyazaki Faculty of Medicine
2021.10 - 2024.09
-
University of Miyazaki Faculty of Medicine College Hospital
2016.04 - 2024.09
-
University of Miyazaki Faculty of Medicine
2015.10 - 2021.09
External Career 【 display / non-display 】
-
University of Miyazaki Faculty of Medicine School of Medicine Surgery study course urology study field Professor
2009.5
-
京都大学大学院医学研究科 器官外科学講座 泌尿器科学 准教授
2007.4 - 2009.4
-
京都大学大学院医学研究科 器官外科学講座 泌尿器科学 助教授
2003.11 - 2007.3
-
京都大学大学院医学研究科 器官外科学講座 泌尿器科学 講師
2001.10 - 2003.10
-
京都大学医学部附属病院 泌尿器科 助手
1997.1 - 2001.9
Professional Memberships 【 display / non-display 】
Papers 【 display / non-display 】
-
Potential effectiveness of local radiotherapy for extending survival and reducing symptomatic local events in patients with de novo metastatic prostate cancer. Reviewed
Terada N, Mizowaki T, Saito T, Yokomizo A, Kohei N, Tabata KI, Shiota M, Takahashi A, Shimazui T, Goto T, Hashimoto Y, Fujii M, Tomida R, Sakurai T, Hashimoto K, Kawamura S, Teraoka S, Sakamoto S, Kimura T, Kamiyama M, Narita S, Tanaka N, Kato T, Kato M, Osawa T, Kojima T, Inoue T, Sugimoto M, Nishiyama H, Kamoto T, Japanese Urological Oncology Group.
BJUI compass 1 ( 5 ) 165 - 173 2020.11
Authorship：Last author Language：English Publishing type：Research paper (scientific journal)
DOI： 10.1002/bco2.35
-
Shiota M., Terada N., Kimura T., Kitamura H., Kamoto T., Eto M.
International Journal of Urology 30 ( 12 ) 1197 - 1199 2023.12
Publishing type：Research paper (scientific journal) Publisher：International Journal of Urology
DOI： 10.1111/iju.15273
-
Yamaguchi T., Goya M., Higashijima K., Tobu S., Sato R., Tatarano S., Mukai S., Uemura K.I., Tatsugami K., Tsubouchi K., Shida Y., Ishii T., Sakai H., Matsuoka H., Haga N., Eto M., Igawa T., Kamoto T., Enokida H., Shin T., Noguchi M., Fujimoto N., Saito S., Kamba T.
Japanese Journal of Clinical Oncology 53 ( 9 ) 837 - 844 2023.9
Language：English Publishing type：Research paper (scientific journal) Publisher：Japanese Journal of Clinical Oncology
Objectives: To understand the real-world outcomes for patients with penile cancer in the Kyushu-Okinawa area before the introduction of practice guidelines in Japan. Methods: We retrospectively collected medical information on patients with penile squamous cell carcinoma and penile intraepithelial neoplasia at 12 university hospitals and their affiliated hospitals in the Kyushu-Okinawa area from January 2009 to December 2020. Patients with unknown clinical stage were excluded. Patient background characteristics and survival, as well as pretreatment factors involved in survival, were investigated. Results: A total of 196 patients were included. Patients with clinical stage 0, I, IIA, IIB, IIIA, IIIB and IV comprised 9.7, 26.0, 22.4, 2.6, 10.7, 14.3 and 14.3%, respectively. The median follow-up was 26 months, and the mean 5-year overall survival and cancer-specific survival rates were 74.3 and 79.8%, respectively. On univariate analysis, tumor diameter ≥ 30 mm, penile shaft tumor, Eastern Cooperative Oncology Group performance status ≥ 1, cT ≥ 3, cN ≥ 2 and cM1 were associated with significantly poorer cancer-specific survival. On multivariate analysis, pretreatment factors of cN ≥ 2 (hazard ratio, 32.5; 95% confidence interval, 5.08-208; P = 0.0002), Eastern Cooperative Oncology Group performance status ≥ 1 (4.42; 1.79-10.9; P = 0.0012) and cT ≥ 3 (3.34; 1.11-10.1; P = 0.0319) were identified as independent prognostic factors. Conclusions: The study revealed basic data for future penile cancer treatment and research, including survival rates according to clinical stages, and identified cN ≥ 2, Eastern Cooperative Oncology Group performance status ≥ 1 and cT ≥ 3 at initial diagnosis as independent prognostic factors. Evidence for penile cancer in Japan is particularly scarce, and future large-scale prospective studies are warranted.
DOI： 10.1093/jjco/hyad053
-
Genome-wide association studies in advanced prostate cancer: KYUCOG-1401-A study
Shiota M., Tatarano S., Kamoto T., Matsuyama H., Sakai H., Igawa T., Kamba T., Fujimoto N., Sekine Y., Kimura H., Narita S., Terada N., Momozawa Y., Akamatsu S., Habuchi T., Yokomizo A., Naito S., Eto M.
Endocrine-Related Cancer 30 ( 7 ) 2023.7
Publishing type：Research paper (scientific journal) Publisher：Endocrine-Related Cancer
Androgen-deprivation therapy (ADT) has been widely used for the treatment of advanced prostate cancer. However, prognosis and adverse events (AEs) vary among patients. This study aimed to identify genetic markers able to predict the outcome of ADT. Japanese patients treated with primary ADT for advanced prostate cancer in the KYUCOG-1401 trial were enrolled as a development set. A distinct population of advanced prostate cancer cases treated with ADT was included as a validation set. Single-nucleotide polymorphisms (SNPs) associated with radiographic progression-free survival (rPFS) at 1 year and AEs including de novo diabetes mellitus (DM), arthralgia, and de novo dyslipidemia were identified in the development set by a genome-wide association study (GWAS). The SNPs associated with rPFS in the development study were then genotyped in the validation set. GWAS followed by validation identified SNPs (rs76237622 in PRR27 and rs117573572 in MTAP) that were associated with overall survival (OS) in ADT. A genetic prognostic model using these SNPs showed excellent predictive efficacy for PFS and OS in ADT. In addition, GWAS showed that several SNPs were associated with de novo DM, arthralgia, and de novo dyslipidemia in ADT. This study identified novel multiple SNPs that correlated with outcomes in ADT. Future studies on correlations affecting the therapeutic efficacy of ADT-based combination therapies would make a valuable contribution to the development of personalized medicine.
DOI： 10.1530/ERC-23-0044
-
A case of hyperammonemia occurring during treatment of metastatic renal cell carcinoma with axitinib
Kimura S., Fujisaki Y., Onizuka C., Hasuike S., Sato Y., Mukai S., Kamoto T.
IJU Case Reports 6 ( 4 ) 206 - 210 2023.7
Publishing type：Research paper (scientific journal) Publisher：IJU Case Reports
Introduction: Although the incidence of hyperammonemia as an adverse event of tyrosine kinase inhibitors is quite low, several cases of tyrosine kinase inhibitor associated hyperammonemia have been reported. We report a case of hyperammonemia, that occurred during combined treatment with axitinib and pembrolizumab in a metastatic renal cell carcinoma patient without hepatic disorder or liver metastases. Case presentation: A 77-year-old Japanese woman was diagnosed with metastatic renal cell carcinoma and was treated with pembrolizumab and axitinib. Both agents were subsequently discontinued due to hyperammonemia with hypothyroidism. After recovery, the patient resumed single-agent therapy with axitinib. However, hyperammonemia and hypothyroidism occurred again, suggesting axitinib-inducible adverse event. After nephrectomy, a lower dose of axitinib was restarted and continued safely for residual metastases under prophylactic treatment with aminoleban, lactulose, and levothyroxine. Conclusion: The rare occurrence of hyperammonemia should be considered during treatment with VEGFR- targeted tyrosine kinase inhibitor including axitinib, and supportive prophylactic medication may be useful.
DOI： 10.1002/iju5.12586
Books 【 display / non-display 】
-
賀本 敏行, 都築 豊徳（ Role： Sole author）
総合医学社 2021 （ ISBN:9784883787203 ）
-
高橋 悟, 賀本 敏行, 菊地 栄次, 杉本 幹史, 安井 孝周, 赤座 英之（ Role： Sole author）
医学図書出版 2021 （ ISBN:9784865174519 ）
Language：Japanese Book type：Scholarly book
-
今日の診療のためにガイドライン外来診療2015
泉孝英、他（ Role： Joint author）
日経メディカル開発 2015.3
Language：Japanese Book type：Scholarly book
-
国試カンファレンス あなむね
賀本敏行、神波大己、他（ Role： Joint author）
医学評論社 2014.6
Language：Japanese Book type：Scholarly book
-
第109回医師国家試験問題解説書
賀本敏行、他（ Role： Joint author）
医学評論社 2014.4
Language：Japanese Book type：Scholarly book
MISC 【 display / non-display 】
-
Future direction of urologic surgery - What should we learn from the change of surgical procedure
Kamoto T., Sugimoto M.
Nishinihon Journal of Urology 82 ( 1 ) 3 - 4 2020.4
Language：Japanese Publishing type：Rapid communication, short report, research note, etc. (scientific journal) Publisher：Nishinihon Journal of Urology
-
【なぜそれが大切?術式別観察ポイントとその根拠】 尿管皮膚瘻造設術の観察ポイントとその根拠
向井尚一郎, 深尾理, 賀本敏行
泌尿器ケア 17 ( 10 ) 985 - 989 2012.10
Language：Japanese Publishing type：Article, review, commentary, editorial, etc. (scientific journal) Publisher：メディカ出版
-
【泌尿器病理I-前立腺と腎臓-】 今日の前立腺癌の治療法
月野浩昌, 賀本敏行
病理と臨床 30 ( 9 ) 941 - 948 2012.9
Language：Japanese Publishing type：Article, review, commentary, editorial, etc. (scientific journal) Publisher：文光堂
-
【明日を見据えた前立腺癌診療】 Key words 前立腺癌の今後の薬物療法への期待
賀本敏行
カレントテラピー 30 ( 9 ) 968 - 969 2012.9
Language：Japanese Publishing type：Article, review, commentary, editorial, etc. (scientific journal) Publisher：ライフメディコム
-
【骨転移のマネジメント】 前立腺癌治療と骨転移マネジメント
賀本敏行
癌と化学療法 39 1178 - 1182 2012.7
Language：Japanese Publishing type：Article, review, commentary, editorial, etc. (scientific journal) Publisher：癌と化学療法社
Presentations 【 display / non-display 】
-
進行性/去勢抵抗性前立腺癌治療に於ける骨マネジメントー骨転移治療のポイントは？－
賀本敏行
第69回西日本泌尿器科学会総会
Event date： 2017.11.9 - 2017.11.12
Language：Japanese Presentation type：Public lecture, seminar, tutorial, course, or other speech
-
Differential use of chemotherapy and novel hormone therapy for castration-resistant prostate cancer
賀本敏行
第15回日本臨床腫瘍学会学術集会
Event date： 2017.7.27 - 2017.7.29
Language：Japanese Presentation type：Symposium, workshop panel (nominated)
-
Update on Prostate Cancer Biopsy Reporting International conference
賀本敏行
Advancements in Urology 2017 in San Diego
Event date： 2017.1.11 - 2017.1.14
Language：Japanese Presentation type：Public lecture, seminar, tutorial, course, or other speech
-
泌尿器細胞診報告様式 2015 に沿った細胞診断ーリスクの検証ー
賀本敏行
第55回日本臨床細胞学会秋季大会
Event date： 2016.11.19
Language：Japanese Presentation type：Symposium, workshop panel (nominated)
-
去勢抵抗性前立腺癌とは
賀本敏行
日本病理学会第 10 回診断病理サマーフェスト
Event date： 2016.9.4
Language：Japanese Presentation type：Oral presentation (invited, special)
Grant-in-Aid for Scientific Research 【 display / non-display 】
-
転移性CRPCにおける、HGF/METパスウェイを標的とした新規治療法の開発
Grant number：23K08737 2023.04 - 2026.03
独立行政法人日本学術振興会 科学研究費基金 挑戦的研究(萌芽)
Authorship：Principal investigator
-
ヒト化マウスを用いた腎細胞癌PDXモデルの樹立とMET阻害薬効果予測因子の同定
Grant number：22K09506 2022.04 - 2025.03
独立行政法人日本学術振興会 科学研究費補助金 基盤研究(C)
Authorship：Coinvestigator(s)
-
CRPCにおけるCAVEOLIN-1,2関連シグナルを介した新規治療法の探索
Grant number：15K10597 2015.04 - 2018.03
科学研究費補助金 基盤研究(C)
Authorship：Principal investigator
去勢抵抗性前立腺癌に対するCAVEOLINを介する新規治療法を開発する。
-
進行性前立腺癌における新しい治療ターゲットの探索
Grant number：24592398 2012.04 - 2015.03
科学研究費補助金 基盤研究(C)
Authorship：Principal investigator
進行性前立腺癌における新しい治療ターゲットの探索
Past consigned research fund received 【 display / non-display 】
-
A Phase 3 Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations
2018.08 - 2022.04
Investigational New Drug Test
Consigned research type：Investigational New Drug Test
-
A randomized, double-blind, placebo-controlled Phase III study of ODM-201 versus placebo in addition to standard androgen deprivation therapy and docetaxel in patients with metastatic hormone-sensitive prostate cancer
2017.04 - 2022.11
Investigational New Drug Test
Consigned research type：Investigational New Drug Test
-
A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Apalutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Subjects with Metastatic Hormonesensitive Prostate Cancer (mHSPC)
2016.02 - 2022.03
Investigational New Drug Test
Consigned research type：Investigational New Drug Test
-
A Phase 3 Randomized, Placebo-controlled Double-blind Study of JNJ-56021927 inCombination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)
2015.10 - 2021.12
Investigational New Drug Test
Consigned research type：Investigational New Drug Test
-
A phase III randomized, double-blind, placebo-controlled trial of radium-223 dichloride in combination with abiraterone acetate and prednisone/prednisolone in the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve subjects with bone predominant metastatic castration-resistant prostate cancer (CRPC)
2015.04 - 2021.03
Investigational New Drug Test
Consigned research type：Investigational New Drug Test
Available Technology 【 display / non-display 】
-
泌尿器科領域悪性腫瘍における浸潤・転移機構の解明
腎無形成マウスモデルを使用した尿管芽浸潤障害 (FUBI)の解明
宮崎泌尿器科がんデータベース(MUCD)を用いたがん診断と治療の検証Related fields where technical consultation is available：泌尿器がんおよび泌尿器疾患の臨床データ、臨床サンプルの収集
泌尿器がんのゼノグラフトモデル（PDX）の作製
骨転移マウスモデルの作製Message：泌尿器腫瘍は基本的に高齢者の悪性腫瘍であり、高齢化に従って患者数、死亡者数は右肩上がりです。実際の患者さんのデータベースと、基礎研究の融合を目指しています。
Committee Memberships 【 display / non-display 】
-
日本泌尿器科学会 理事
2019.4
Committee type：学協会
NCD運営委員会委員長